Each of the three Projects within the Program Project will require purified native and oxidatively modified lipoproteins, access to human clinical material with known clinical follow-up and a source of native, mutant or site-specific post-translationally modified proteins of interest to use in their studies. The Human Clinical Material & Protein Engineering Core (Scientific Core 1; SC1) will provide all of these services, allowing for expansion of the scope, scale and clinical significance of proposed studies in each Project of this Program. The Human Clinical Material & Protein Engineering Core has 3 primary objectives: First, the core will facilitate human clinical and translational studies of Program investigators by providing the following services: (i) Coordination of all IRB paperwork, advertising / consenting of volunteers, contact of patients with specific phenotypes (e.g. high LP(a) levels), and phlebotomy services. (ii) Using standardized SOP for isolation and characterization of the following human biological materials: whole blood (e.g. for PMN and MPO isolation); plasma; serum; isolated lipoproteins (e.g. VLDL, LDL, HDL and LP(a)). (iii) Coordination of monocyte isolation via elutriation. (iv) Coordination of access to archival human clinical specimens (plasma, serum, DNA) from the GeneBank cohort for proposed clinical studies. (v) Access to human clinical specimens available within the Center for Cardiovascular Diagnostics & Prevention. Second, the core will assist Program investigators with protein engineering and antibody generation by providing the following services: (i) assist investigators with design, expression, and purification of distinct classes of wild type and mutant forms of proteins. (ii) Generation of low endotoxin recombinant proteins for in vivo studies. (iii) Orthogonal amino acid incorporation using tRNA mutants to specifically form individual recombinant proteins harboring unnatural amino acids (e.g. nitrotyrosine, chlorotyrosine, N?-acetyl-lysine). And (iv) assistance in generation of both polyclonal and monoclonal antibodies. Finally, the core will serve as an educational and training hub for Program investigators, especially students and fellows. Centralizing these aspects of the work and training will greatly enhance the significance, innovation, and clinical relevance of studies performed in each Project of this Program.

Public Health Relevance

Scientific Core 1 (SC1). Project Narrative The Human Clinical Material & Protein Engineering Core supports each Project within this Program through: (i) assistance in all human clinical and translational studies proposed; assistance in state-of-the-art protein engineering and antibody generation; and serving as a centralized hub for training and education of Program investigators. The core will thus greatly enhance the scope, scale, significance, innovation and clinical relevance of studies performed in each Project of this Program.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL076491-14
Application #
9478682
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Hasan, Ahmed a K
Project Start
2004-08-01
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
14
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Type
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Szpak, Dorota; Izem, Lahoucine; Verbovetskiy, Dmitriy et al. (2018) ?M?2 Is Antiatherogenic in Female but Not Male Mice. J Immunol 200:2426-2438
Sarvestani, Samaneh K; Signs, Steven A; Lefebvre, Veronique et al. (2018) Cancer-predicting transcriptomic and epigenetic signatures revealed for ulcerative colitis in patient-derived epithelial organoids. Oncotarget 9:28717-28730
Li, Xinmin S; Wang, Zeneng; Cajka, Tomas et al. (2018) Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk. JCI Insight 3:
Arif, Abul; Yao, Peng; Terenzi, Fulvia et al. (2018) The GAIT translational control system. Wiley Interdiscip Rev RNA 9:
Eswarappa, Sandeep M; Potdar, Alka A; Sahoo, Sarthak et al. (2018) Metabolic origin of the fused aminoacyl-tRNA synthetase, glutamyl-prolyl-tRNA synthetase. J Biol Chem 293:19148-19156
Halawani, Dalia; Gogonea, Valentin; DiDonato, Joseph A et al. (2018) Structural control of caspase-generated glutamyl-tRNA synthetase by appended noncatalytic WHEP domains. J Biol Chem 293:8843-8860
Brown, J Mark; Hazen, Stanley L (2018) Microbial modulation of cardiovascular disease. Nat Rev Microbiol 16:171-181
Senthong, Vichai; Hudec, Timothy; Neale, Sarah et al. (2017) Relation of Red Cell Distribution Width to Left Ventricular End-Diastolic Pressure and Mortality in Patients With and Without Heart Failure. Am J Cardiol 119:1421-1427
Pamir, Nathalie; Hutchins, Patrick M; Ronsein, Graziella E et al. (2017) Plasminogen promotes cholesterol efflux by the ABCA1 pathway. JCI Insight 2:
Arif, Abul; Terenzi, Fulvia; Potdar, Alka A et al. (2017) EPRS is a critical mTORC1-S6K1 effector that influences adiposity in mice. Nature 542:357-361

Showing the most recent 10 out of 271 publications